// App-Quantinova.ai

1486 : Pharmacodynamic response to HER2/CD3 bispecific antibody (HER2-TDB): evidence of T-cell recruitment and further rationale for combination treatment with anti-PD-L1

Researchers

Presenter

  • Ji Li

Principal Investigators

  • Maria Hristopoulos

  • Robyn Clark

  • Jennifer Johnston

  • Dion Slaga

  • Bu-Er Wang

  • Rafael Cubas

  • Klara Totpal

  • Melissa R. Junttila

  • Teemu T. Junttila

Medical Centers

  • Roche/Genentech, South San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Trastuzumab

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved